chapter  21
12 Pages

Validation of exposure and risk biomarkers: aflatoxin as a case study

ByJohn D. Groopman, Peta E. Jackson, Paul Turner, Christopher P. Wild, Thomas W. Kensler

I. Introduction .............................................................................................308 II. Molecular epidemiological studies of aflatoxin and human liver

cancer ........................................................................................................309 III. Aflatoxin exposure and HBV infection in children ..........................310 IV. Aflatoxin exposure and mutations in the

p53

tumor suppressor gene ........................................................................................................... 311

V. Biomarkers and liver cancer prevention.............................................314 VI. Summary ..................................................................................................316